Biphasic effects of IL-27 during *Staphylococcus aureus* implant-associated osteomyelitis in mice

Yugo Morita^a, Anthony M. Franchini^b, John R. Owen^c, John C. Martinez^a,
John L. Daiss^{a,d}, Karen L. de Mesy Bentley^{a,d,e}, Stephen L. Kates^c,
Edward M. Schwarz^{a,e} and #Gowrishankar Muthukrishnan^{a,e}

^aCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA

^bDepartment of Environmental Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

^cDepartment of Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, USA

^dDepartment of Orthopaedics, University of Rochester Medical Center, Rochester, NY, USA

^eDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA

#Corresponding Author:

Gowrishankar Muthukrishnan, Ph.D.
The Center for Musculoskeletal Research
Department of Orthopaedics
University of Rochester Medical Center
601 Elmwood Avenue, Box 665
Rochester, NY 14642
Phone: 585-273-5632, **Fax:** 585-276-2177
E-mail: Gowri_Shankar@URMC.Rochester.edu

Conflict of interest statement: The authors have declared that no conflict of interest exists.

Running title: Biphasic effects of IL-27 during *S. aureus* osteomyelitis

Keywords: interleukin-27, *S. aureus*, osteomyelitis, staphylococcal abscess, osteolysis, host-pathogen interactions

33 Abstract

34 Interleukin-27 is a pleiotropic cytokine whose reported functions during bacterial infections are debated
 35 as an area of active research. To address this, we investigated the role of IL-27 signaling during
 36 *Staphylococcus aureus* osteomyelitis. Clinically, we observed elevated serum IL-27 levels (20-fold
 37 higher, $p < 0.05$) in patients with *S. aureus* osteomyelitis compared to uninfected patients undergoing
 38 elective total joint replacement. Remarkably, IL-27 serum levels immediately following septic death
 39 were 60-fold higher vs. uninfected patients ($p < 0.05$), suggesting that IL-27 may be a biomarker of end-
 40 stage infection and/or cytokine storm. To test this, we hypothesized that IL-27 mediates bacterial
 41 clearance during the acute phase of *S. aureus* osteomyelitis, and subsequently suppresses inflammation
 42 to prevent cytokine storm and osteolysis during chronic infection. In mice, we observed that systemic
 43 IL-27 delivery by a recombinant adeno-associated viral vector (rAAV-IL-27) ameliorates surgical site
 44 soft tissue infection and peri-implant bone loss during the establishment of implant-associated *S. aureus*
 45 osteomyelitis. This effect was not observed in IL-27 receptor α knock-out mice, suggesting a direct role
 46 of IL-27/IL-27R signaling on immune and bone cell functions. Examination of IL-27-mediated immune
 47 responses via transcriptome analyses of infected tibiae demonstrated that IL-27 is a biphasic cytokine
 48 with IL-27/IL-27R activating immunostimulatory responses including Th17, IL-2, TLR, and iNOS
 49 signaling early, and subsequently suppressing these pathways during chronic infection. Ex vivo
 50 confirmation using murine macrophages revealed that IL-27 co-stimulates TLR signaling to increase the
 51 production of nitric oxide, and immunomodulatory cytokines such as IL-10, IL-21, IL-31, and TNF- β ,
 52 but is not a chemokine.

53 **Author Summary**

54 *Staphylococcus aureus* is the most common pathogen in orthopaedic infections, and hard-to-treat
 55 (MRSA) strains cause >50% of these infections. Thus, there is an urgent need to develop
 56 immunotherapies to treat these life-threatening *S. aureus* infections. Currently, the role of
 57 multifunctional IL-27 on *S. aureus* osteomyelitis is unknown. In a clinical study, we observed that IL-27
 58 is an important biomarker for identifying *S. aureus* osteomyelitis patients, and that elevated serum IL-27
 59 levels correlated with adverse clinical outcomes, such as septic death. In our efforts to uncover the
 60 underlying mechanisms, we reveal that IL-27 is a biphasic cytokine, activating proinflammatory
 61 immune pathways, including Th17 responses, early during acute *S. aureus* osteomyelitis, and
 62 subsequently repressing them during the chronic phase to prevent cytokine storm and bone damage.
 63 These results indicate that immune modulation of IL-27/IL-27R signaling could be a viable therapeutic
 64 strategy in mitigating *S. aureus* osteomyelitis.

65 Introduction

66 Deep bone infections continue to be the bane of orthopaedic surgery, with infection rates essentially
67 remaining at 1-2% for elective surgery over the past 50 years, despite significant medical advances [1-
68 3]. *Staphylococcus aureus* is the major pathogen in orthopaedic infections. It is responsible for causing
69 10,000-20,000 prosthetic joint infections (PJI) annually in the United States alone [4, 5] and 30-42% of
70 fracture-related infections (FRI) [6, 7]. Unfortunately, these difficult-to-treat *S. aureus* bone infections
71 are associated with poor clinical outcomes and high recurrence rates following revision surgery [8, 9].
72 With increasing methicillin-resistant *S. aureus* (MRSA) osteomyelitis incidence rates, and emerging
73 strains with pan-resistance [10, 11], there is an urgent need for novel immunotherapies to supplement
74 existing antibiotic therapies.

75 *S. aureus* causes the most lethal form of human sepsis with a 10% mortality rate, and a
76 catastrophic outcome of osteomyelitis is death due to sepsis and multiple organ failure [12, 13]. The
77 mechanisms behind *S. aureus* osteomyelitis-induced sepsis are largely unknown. Interestingly, several
78 studies have reported elevated serum IL-27 levels during sepsis, suggesting that IL-27 could potentially
79 be a diagnostic biomarker of sepsis [14-19]. IL-27 is a heterodimeric cytokine belonging to the IL-12
80 cytokine family and is mainly produced by antigen presenting cells such as macrophages, monocytes,
81 and dendritic cells [20, 21]. It is composed of IL-27p28 and EBI3 subunits, and signals through a
82 heterodimeric cell surface receptor composed of IL-27 receptor α (IL-27R α) and gp130 [22, 23]. Like
83 IL-12, it signals mainly through the JAK-STAT intracellular pathway and plays a central role in multiple
84 immune regulation activities. It downregulates Th17 differentiation, stimulates regulatory T cell
85 formation, and directly modifies CD4⁺ T cell effector functions to induce anti-inflammatory IL-10 [20,
86 21, 24, 25]. Studies involving cecal ligation and puncture (CLP)-induced bacterial sepsis and *S. aureus*
87 pneumonia following influenza demonstrated that IL-27 regulates enhanced susceptibility to infection
88 by attenuating Th17 immunity and promoting IL-10 induction [26, 27]. These studies highlight the

importance of IL-27 in immune suppression. On the other hand, IL-27 has been reported to promote proliferation and differentiation of hematopoietic stem cells [28], increase production of proinflammatory cytokines by monocytes [29, 30], and induce Th1 differentiation [31]. Currently, the role of IL-27 in host immunity during *S. aureus* osteomyelitis is unknown. Here, we tested the hypothesis that IL-27 is a biphasic cytokine that enhances bacteria killing via promoting inflammation early during acute *S. aureus* osteomyelitis, and subsequently suppresses inflammation during chronic bone infection to prevent cytokine storm and osteolysis. Consistent with this theory, we report that IL-27 is induced in patients with *S. aureus* osteomyelitis, and elevated serum IL-27 correlated with septic death in these patients. Examining IL-27's role in mice revealed that this cytokine is crucial for carefully balancing the host immunostimulatory and immunosuppressive responses during *S. aureus* osteomyelitis.

Results

S. aureus infection induces IL-27 secretion in patients and in mice

To better understand host immune responses against *S. aureus* osteomyelitis, we analyzed sera from healthy people, orthopaedic patients with culture-confirmed *S. aureus* bone infections, and patients who died from septic *S. aureus* osteomyelitis. Serum IL-27 levels were significantly elevated in infected patients compared to uninfected individuals (20-fold higher, $p < 0.05$). Remarkably, IL-27 levels immediately following septic death were 60-fold higher (**Fig. 1A**, $p < 0.05$), suggesting that IL-27 could be an essential biomarker for *S. aureus* osteomyelitis-induced septic death. Indeed, formal analyses of IL-27 as a diagnostic biomarker using receiver operator characteristic (ROC) curve analysis revealed a high area under the curve (AUC) of 0.922 (**Fig. 1B**, $p < 0.0001$). We also evaluated whether *S. aureus* infection directly induces IL-27 production in murine macrophages in vitro. Interestingly, in both RAW 264.7 macrophages and murine bone marrow-derived macrophages, *S. aureus* induced significant IL-27

113 secretion 24 hours post infection in M0, M1, and M2 murine macrophages (**Fig. 1C-D**, $p < 0.05$).
 114 Collectively, these data indicate an important role for IL-27 in host immunity against *S. aureus*
 115 infections.

Systemic IL-27 delivery inhibits draining abscess formation and bone osteolysis during establishment of *S. aureus* osteomyelitis

118 Having established an association between IL-27 and *S. aureus* osteomyelitis in patients and mice, we
 119 next examined if IL-27 mediates bacterial clearance during *S. aureus* osteomyelitis using our well-
 120 established murine model of osteomyelitis [32-36]. Mice were challenged with bioluminescent MRSA
 121 (USA300 LAC::lux) via transtibial implantation of a contaminated stainless-steel implant following
 122 intramuscular injection of rAAV-IL-27 or adeno-associated virus expressing recombinant GFP (rAAV-
 123 GFP, control). Before the in vivo infection experiment, we confirmed exogenous IL-27 expression in
 124 mouse sera out to day 24 following intramuscular injection of rAAV-IL-27 (**Fig. 2A**). While rAAV-IL-
 125 27 treatment did not show an effect on in vivo *S. aureus* growth as assessed by bioluminescent intensity
 126 (BLI) (**Fig. 2B**), rAAV-IL-27 treated mice showed greater body weight recovery following septic-
 127 surgery compared to rAAV-GFP treated animals (**Fig. 2C**). Remarkably, rAAV-IL-27 treated animals
 128 showed much smaller draining abscess formation at the site of bone infection (**Fig. 2D**). Ex vivo CFU
 129 analyses confirmed that the bacterial load in surgical site soft tissues was significantly lower in rAAV-
 130 IL-27 treated mice (**Fig. 2E**). Moreover, high-resolution μ CT demonstrated that peri-implant osteolysis
 131 was decreased in mice treated with rAAV-IL-27 compared to rAAV-GFP treated animals (**Fig. 2F**).
 132 These results demonstrate that IL-27 affects abscess formation and bone osteolysis. Interestingly, CFU
 133 quantification on the implants revealed similar bacterial loads between groups suggesting that systemic
 134 IL-27 treatment does not affect biofilm formation on the implant. Indeed, scanning electron microscopy
 135 (SEM) interrogation confirmed these findings (**Supplemental Fig. 1**).

Systemic IL-27 effects on *S. aureus* implant associated osteomyelitis in IL-27R α ^{-/-} mice

Two possible scenarios can lead to the observed suppression of *S. aureus* SACs and reduced bone osteolysis at the surgical site. IL-27 could be a chemokine attracting myeloid cells to the site of *S. aureus* infection. Alternatively, IL-27/IL-27R signaling pathway could extrinsically be inducing chemotaxis of innate immune cells to the infection site. First, we examined if IL-27 is chemotactic of myeloid cells. In vitro chemotaxis assay using granulocytic HL-60 cells revealed that IL-27 did not promote migration of granulocytes through the Boyden chambers (**Supplemental Fig. 2**). IL-27 was also not chemotactic of primary bone marrow-derived macrophages (data not shown). Next, to test whether IL-27/IL-27R signaling was inducing chemotaxis of immune cells to cause the observed phenotype, we repeated the in vivo *S. aureus* osteomyelitis experiments using IL-27 receptor α knock out (IL-27R $\alpha^{-/-}$) mice. At 14 days post infection, body weight changes (**Fig. 3A**) and BLI (**Fig. 3B**) were similar between IL-27R $\alpha^{-/-}$ mice treated with rAAV-IL-27 or rAAV-GFP. Most interestingly, ex vivo CFU on the implants, surgical site soft tissues, and tibia were similar in IL-27R $\alpha^{-/-}$ mice (**Fig. 3D**). Furthermore, no difference was detected in draining abscess formation on these implants (**Fig. 3C**) and gross assessment of peri-implant osteolysis (data not shown) between groups. These data indicate that the effects of rAAV-IL-27 on *S. aureus* osteomyelitis in WT mice were due to IL-27/IL-27R signaling.

Identification of systemic IL-27 affected pathways during the establishment of implant-associated osteomyelitis

Next, we sought to elucidate the mechanism of IL-27/ IL-27R signaling effects on *S. aureus* osteomyelitis via unbiased gene expression studies. MRSA-infected mouse tibiae from rAAV-IL-27- and rAAV-GFP-treated groups were harvested on days 1, 3, 7, and 14 post-septic surgery and subjected to bulk RNA sequencing. The number of differentially (up-regulated or down-regulated) expressed genes (DEGs) on each day are shown in **Fig. 4B**. Venn diagram analyses of DEGs revealed *IL-27*, prostaglandin E synthase (*PTGES*), and sodium/myo-inositol cotransporter (*SLC5A3*) to be the common overlapping nodal points across all time points (**Fig. 4C**). Expectedly, IL-27 expression in the infected

161 tibia was significantly up-regulated in mice treated with rAAV-IL-27 compared to rAAV-GFP at all
162 time points (**Fig. 4D**), suggesting a positive feedback effect [37].

163 Additionally, Ingenuity Pathway Analysis (IPA) was performed to identify canonical pathways
164 enriched between rAAV-IL-27 and rAAV-GFP treated animals (**Fig. 4E**). Examination of enriched
165 pathways involved in innate and adaptive immunity revealed that pro-inflammatory immune pathways
166 including IL-23 signaling pathway, Th17 activating pathway, IL-17 signaling, and IL-2 signaling were
167 activated in rAAV-IL-27 treated mice during the acute phase of *S. aureus* osteomyelitis (day 1 post-
168 surgery) compared to rAAV-GFP treated animals. Interestingly, these pathways were suppressed at later
169 time points, especially on day 14, which represents the chronic phase of the disease. These data strongly
170 indicate that IL-27 could be a biphasic cytokine, which activates pro-inflammatory immune pathways
171 early upon *S. aureus* infection and suppresses them late to prevent tissue damage and cytokine storm.

IL-27-mediated induction of pro-inflammatory cytokines early during *S. aureus* osteomyelitis and their down-regulation during chronic infection

174 RNAseq analyses revealed that genes associated with IL-23 signaling (**Fig. 5A**) and Th17 activation
175 pathway (**Fig. 5B**) were significantly up-regulated in mice treated with rAAV-IL-27 on day 1 post-
176 surgery, compared to rAAV-GFP animals. These genes include *IL17A*, *IL-17F*, *IL-21*, and *IL12B*. We
177 confirmed that IL-27-pretreated murine macrophages induce moderate production of pro-inflammatory
178 cytokines such as IL-21, IL-31, and TNF- β early in response to *S. aureus* infection (**Table 1**). Of note,
179 anti-inflammatory cytokine IL-10 was also modestly up-regulated in these macrophages suggesting a
180 pleiotropic nature for IL-27. Remarkably, pro-inflammatory cytokine coding genes such as *IL17A*,
181 *IL12A*, *TNF*, and *IL-6* were down-regulated later at day 14 during the chronic phase of infection (**Fig.**
182 **5A-B**). Utilizing the DEG data, we also assessed the top regulatory networks in IPA for these genes to
183 provide further insight into the effects of differential gene expression in our dataset (**Supplemental**
184 **Table 1**). Our analyses indicated that regulatory genes such as HSP90B1 and EGR2, up-regulated pro-
185 inflammatory cytokine-coding genes *IL21*, *IL17A*, *IL12B*, *IL17F*, and *RORC* in rAAV-IL-27 treated

mice. *RORC* encode the Th17 master transcription factor ROR γ t [38]. Additionally, transcriptome analyses revealed that immunostimulatory genes associated with Toll-like receptor (TLR) (**Fig. 5C**) and iNOS (**Fig. 5D**) signaling pathways were suppressed at later stages of *S. aureus* infection. However, their expression levels during the early infection phase (day 1) were equivocal. Indeed, we confirmed that combination of IL-27 and TLR agonist lipopolysaccharide (LPS) stimulation increased nitric oxide (NO $^{\cdot-}$) production in primary macrophages, suggesting a co-immunostimulatory effect on TLR signaling (**Supplemental Fig. 3**). Collectively, these results indicate that IL-27 modulates immune homeostasis by promoting the production of pro-inflammatory cytokines early upon *S. aureus* infection and suppressing them late to prevent tissue damage.

rAAV-IL-27 treatment inhibits osteoclast formation during implant-associated osteomyelitis

μ CT demonstrated that peri-implant osteolysis was decreased in infected mice subjected to rAAV-IL-27 treatment. Therefore, we hypothesized that systemic IL-27 treatment suppresses inflammatory osteoclasts to prevent bone damage during *S. aureus* osteomyelitis. IPA and gene expression analyses revealed that RANK signaling in osteoclasts was suppressed in the infected tibiae of rAAV-IL27 treated animals on days 3, 7, and 14 (**Fig. 4E, 6A**). Histopathology confirmed the suppression effect of IL-27 on osteoclasts (**Fig. 6B**), where systemic IL-27 induced significantly less osteoclast activation in trabecular bone (**Fig. 6C**).

Discussion

Cytokines, including IL-27, are central to mounting an immune response during infection, and elucidation of IL-27 functions throughout infection is essential to our understanding of protective vs. susceptible host immunity [20]. In this study, we examined the role of IL-27 during *S. aureus* osteomyelitis as clinical studies revealed elevated serum IL-27 levels in patients with *S. aureus* bone infections. In mice, we demonstrated that IL-27/IL-27R signaling mediates bacterial clearance during

the acute phase of *S. aureus* osteomyelitis, and suppresses subsequent inflammation to prevent cytokine storm and bone osteolysis during chronic infection.

A remarkable finding of our study is that serum IL-27 levels were highly diagnostic of *S. aureus* osteomyelitis in patients (AUC=0.922). Previous studies have shown that serum IL-27 levels are elevated in sepsis patients, indicating its potential as a diagnostic biomarker of sepsis [14-18, 39]. A single-center prospective study demonstrated that serum IL-27 levels could be utilized to achieve AUCs of 0.75 in patients with sepsis [16]. Though IL-27 levels immediately following septic death were 60-fold higher in patients compared to uninfected patients, we couldn't perform AUC calculations due to the low number of septic death patients. Nonetheless, our study indicates that IL-27 could be a diagnostic marker of *S. aureus* osteomyelitis, and more extensive patient cohort studies are required to formally assess its diagnostic potential.

Systemic IL-27 delivery led to amelioration of surgical site soft tissue infection and peri-implant bone loss during the establishment of *S. aureus* osteomyelitis. However, the bacterial loads on the implant or bone were not affected by IL-27 delivery underscoring the ability of *S. aureus* to invade deep within the immune-privileged environment of bone [40]. Interestingly, reduction in abscess formation and bone osteolysis was not observed in IL-27 receptor α knock-out mice, suggesting a direct role of IL-27/IL-27R signaling on immune and bone cell functions. Similarly, Wang et al. showed that administration of recombinant IL-27 improved bacterial clearance and host survival in a rodent model of *Clostridium difficile* infection colitis [41]. Contrastingly, other studies have observed that blockade of IL-27 worsened the severity of sepsis-induced myocardial dysfunction in an endotoxic shock syndrome murine model [42]. Collectively, these studies highlight the diverse effects of IL-27 on various bacterial infections.

Transcriptome analyses of the *S. aureus* infected tibia treated with rAAV-IL-27 revealed that IL-27 is a biphasic cytokine activating pro-inflammatory pathways early during *S. aureus* osteomyelitis and suppressing them late during the chronic phase. From these observations, it is conceivable that IL-27

235 contributes to time-dependent changes in host immunity from acute to chronic *S. aureus* osteomyelitis.
 236 A recent study, using a murine intra-femur osteomyelitis model, demonstrated similar time-dependent
 237 changes in host response during *S. aureus* osteomyelitis using gene expression analyses [43]. We also
 238 revealed that IL-23, Th17 activation, IL-17 signaling, and pro-inflammatory IL-21 were up-regulated
 239 during early *S. aureus* infection. Collectively, these pathways contribute to the expansion of Th17 cells
 240 and induction of Th17-mediated immunity, which are crucial to host defense against bacterial infections
 241 [44, 45]. However, excessive or prolonged Th17 responses due to chronic infection cause tissue damage
 242 and autoimmune diseases [46-48]. In addition to thwarting immune responses, we observed that
 243 systemic IL-27 administration suppresses inflammatory osteoclasts to prevent bone damage during the
 244 chronic phase of *S. aureus* osteomyelitis. This is consistent with the known effects of IL-27 on inhibition
 245 of osteoclastogenesis [49-52]. Collectively, these studies add to the growing body of IL-27 literature
 246 with reported pro-inflammatory and anti-inflammatory effects on various immune cells [24, 29, 30, 53-
 247 58].

248 Here, we propose a schematic model of IL-27-mediated immune homeostasis during *S. aureus*
 249 osteomyelitis (**Fig. 7**). IL-27 promotes host immune reaction against *S. aureus* osteomyelitis by
 250 regulating a diverse set of immunostimulatory and immunosuppressive pathways in a time-dependent
 251 manner. At the onset of *S. aureus* osteomyelitis, IL-27 promotes the production of pro-inflammatory
 252 cytokines [29, 30, 56-58], leading to enhanced bacterial killing by macrophages and neutrophils. In
 253 contrast, at later stages of the infection, IL-27 inhibits the production of pro-inflammatory cytokines [24,
 254 53-55] and osteoclastogenesis [49-52] to prevent cytokine storm and osteolysis. The proposed IL-27
 255 mediated immune homeostasis model is preliminary, and warrants several further investigations. Firstly,
 256 we need to examine the immune cell repertoire in the bone marrow niche that causes IL-27/IL-27R-
 257 mediated effects during *S. aureus* osteomyelitis over time. Secondly, we need to understand IL-27's role
 258 in preventing cytokine storm and internal organ tissue damage during chronic *S. aureus* osteomyelitis in
 259 a more relevant osteomyelitis sepsis murine model. Humanized mice, which are more susceptible to

260 MRSA osteomyelitis-induced sepsis, may be better suited for these studies [59]. Finally, we need to
 261 assess how systemic IL-27 inhibits bone osteolysis by suppressing RANKL-mediated
 262 osteoclastogenesis. These studies will further our understanding of IL-27/IL-27R signaling during *S.*
 263 *aureus* osteomyelitis.

264

265 **Materials and Methods**

266 Bacterial strains

267 Methicillin-resistant *S. aureus* (USA300 LAC) was used for all in vitro experiments, and a
 268 bioluminescent strain of USA300 (USA300 LAC::lux) was used for all in vivo experiments as
 269 previously described [32-34, 36, 59].

270 Ethics Statement and Patient Enrollment

271 Serum samples were collected from *S. aureus* osteomyelitis patients (n=23) and uninfected patients
 272 undergoing elective total joint replacement (n=10). Additionally, serum samples were collected
 273 immediately post-mortem in patients that succumbed to *S. aureus* osteomyelitis sepsis (n=5). All
 274 recruited patients were either part of an international biospecimen registry (AO Trauma Clinical Priority
 275 Program (CPP) Bone Infection Registry) [60] or clinical studies conducted at the Virginia
 276 Commonwealth University. Patients were recruited with local IRB approvals at various institutions, and
 277 patient information was collected in a REDCap database managed by AO Trauma and VCU data
 278 management administrators. Laboratory investigators had access only to de-identified clinical data,
 279 which was provided on request by the data management teams. All ex vivo and in vivo mouse infection
 280 studies were performed at the University of Rochester in accordance with protocols approved by the
 281 Institutional Animal Care and Use Committee at the University.

282 Luminex-based cytokine measurements

283 Serum IL-27 levels were determined in patients via Luminex assay using the Milliplex xMAP Multiplex
 284 Assay (MilliporeSigma) according to the manufacturer's instructions. Primary bone marrow-derived

285 murine macrophages (BMDMs) were pretreated with PBS or murine IL-27 (50 ng/ml from BioLegend)
 286 for 24 hours and then infected with *S. aureus* at MOI = 10 in the presence or absence of murine IL-27
 287 (50 ng/ml) for 24 hours. Subsequently, the cell culture supernatants were harvested from these cells to
 288 measure the following cytokines using a multiarray Milliplex xMAP murine cytokine Magnetic Bead
 289 Panel according to manufacturer's instructions: CD40L, GM-CSF, IFN- γ , IL-1 β , IL-2, IL-4, IL-5, IL-6,
 290 IL-10, IL-13, IL-15, IL-17A, IL-17F, IL-21, IL-22, IL-23, IFN- λ 3/IL-28B, IL-31, IL-33, MIP-
 291 3 α /CCL20, TNF- α , and TNF- β .

In vitro IL-27 induction assay in macrophages

293 Primary BMDMs from 12-week-old C57BL/6 mice (Jackson Laboratory) were isolated from femur and
 294 tibia. After dissection of the femur and tibia from mice, bones were washed in RPMI + 10% FBS, 1%
 295 HEPES, and 1% anti-microbial/anti-mycotic (R10) media before disinfection using 70% ethanol. After
 296 disinfection, the long bones were cut on both ends, and marrow was flushed using a 23G needle and
 297 resuspended in R10 media. After spinning cells down at 500g for ten minutes, the isolated cells were
 298 resuspended in a red lysis buffer to remove red blood cells. Cells were then resuspended again in R10
 299 media with mouse colony-stimulating factor (M-CSF) (25ng/mL) and plated at 5 x 10⁶ cells/plate for 6
 300 days. Subsequently, BMDMs were differentiated with PBS, murine IFN- γ (50 ng/ml from PeproTech) or
 301 murine IL-4 (20 ng/ml from PeproTech) in R10 for 24 hours to generate M0, M1, and M2 cells
 302 respectively [61]. These cells were then infected with *S. aureus* USA300 at MOI = 10 for 24 hours, and
 303 subsequently, the cell culture supernatant was harvested to examine IL-27 secretion using the Mouse IL-
 304 27 Uncoated ELISA kit (Invitrogen).

Reactive nitrogen species induction in murine macrophages

306 Murine BMDMs were pretreated with PBS or murine IL-27 (50 ng/ml from Biolegend) for 24 hours,
 307 and then stimulated with or without LPS (100ng/ml from MilliporeSigma) to induce reactive nitrogen
 308 species production [62], which is important for host defense against bacterial infection [63]. Stimulation
 309 experiments were performed on BMDMs with or without murine IL-27 (50 ng/ml) for 24 hours after

310 pretreatment. Subsequently, nitrite concentrations in cell culture supernatant were determined via Griess
311 reaction assay kit (R&D Systems).

312 Transwell Chemotaxis assay

313 HL-60 cells (ATCC) were differentiated into granulocytes using 100mM dimethylformamide (DMF)
314 (MilliporeSigma), placed on top of Boyden chambers, and chemotaxis assay was performed according
315 to manufacturer's protocol (MilliporeSigma QCM™ Chemotaxis 5 µm 24-Well Cell Migration Assay
316 kit). Briefly, 1×10^6 cells/chamber were subjected to chemotaxis in RPMI media with or without the
317 chemoattractant (human IL-27 (500 ng/ml from PeproTech) or N-formyl-methionyl-leucyl-
318 phenylalanine (fMLP) (800 ng/mL from MilliporeSigma) as positive control)) placed below the
319 chamber, and incubated for 1 hour at 37 °C. Post incubation, cell migration from the chambers was
320 enumerated as relative fluorescence units (RFUs) according to the manufacturer's instructions.

321 Recombinant IL-27-expressing adeno-associated virus vector (rAAV-IL-27) administration

322 To get sustained exogenous IL-27 expression, mice were subjected to intramuscular administration of
323 recombinant murine IL-27-expressing AAV (0.5×10^{12} genome copies/mouse, Vector Biolabs) 7 days
324 prior to *S. aureus* septic surgery [64]. Mice intramuscularly infected with AAV expressing recombinant
325 GFP (0.5×10^{12} genome copies/ mouse, Vector Biolabs) were used as controls.

326 Implant-associated MRSA osteomyelitis in mice

327 C57BL/6 and IL-27Rα deficient mice (IL-27Rα^{-/-}) in the C57BL/6 background used in the study were
328 purchased from Jackson Laboratories and maintained at the University of Rochester animal facilities.
329 All in vivo *S. aureus* challenge experiments in mice utilized our well-validated transtibial implant-
330 associated osteomyelitis model [32-34, 36, 59]. Briefly, L-shaped stainless-steel implant was
331 contaminated with USA300 LAC (5.0×10^5 CFU/mL) grown overnight, and surgically implanted into
332 the tibia of 8-week-old female C57BL/6 mice from the medial to the lateral side. Longitudinal body
333 weight change and bioluminescent intensity at infection site were evaluated, and terminal assessment of
334 CFU (implant, surgical site soft tissue and tibia), peri-implant osteolysis (high-resolution µCT imaging),

335 biofilm formation on the implant (Zeiss Auriga SEM imaging), and histopathology were performed on
 336 day 14 post-septic surgery as described previously [32-34, 36, 59]. Murine infection studies were
 337 performed three independent times, and the resulting data was pooled from these experiments.

338 RNA sequencing of MRSA infected tibia

339 C57BL/6 were intramuscularly injected with rAAV-IL-27 or rAAV-GFP and then challenged with an *S.*
 340 *aureus* contaminated transtibial implant as described above. Infected tibiae were collected on days 1, 3,
 341 7, and 14 post-surgery for RNA sequencing. Tibiae were pulverized in liquid nitrogen (-196 °C) and
 342 homogenized using Bullet Blender Gold (Next Advance). Collection of Total RNA from homogenized
 343 tibia was performed using TRIzol extraction (ThermoFisherScientific) and RNeasy Mini Kits (Qiagen).
 344 Contaminating genomic DNA was removed using TURBO DNase (ThermoFisherScientific). The
 345 TruSeq Stranded Total RNA Library Prep Gold (Illumina) was utilized for next-generation sequencing
 346 library preparation per the manufacturer's instructions. The libraries were sequenced with the Illumina
 347 NovaSeq6000 platform (Illumina). Quality filtering and adapter removal were performed by fastp
 348 version 0.20.0 [65] using the following parameters: "--in1 ../\$(SAMPLE)_R1.fastq.gz --out1
 349 clt_\$(SAMPLE)_R1.fastq.gz --length_required 35 --cut_front_window_size 1 --cut_front_mean_quality
 350 13 --cut_front --cut_tail_window_size 1 --cut_tail_mean_quality 13 --cut_tail -w 8 -y -r -j
 351 \$(SAMPLE)_fastp.json". The remaining high quality processed reads were then mapped to the *Mus*
 352 *musculus* genome reference (GRCm38.p6) with STAR version 2.7.0f [66] using the following
 353 parameters: "--twopassMode Basic --runMode alignReads --genomeDir \$(GENOME) --readFilesIn
 354 \$(SAMPLE) --outSAMtype BAM Unsorted --outSAMstrandField intronMotif --outFilterIntronMotifs
 355 RemoveNoncanonical". The mapped reads were counted within the GRCm38.p6 gene annotations using
 356 the featureCounts read quantification program in Subread version 1.6.4 [67]. Then, the differential
 357 expression analyses and data normalization were performed using DESeq2 version 1.22.1 [68] within
 358 the R version 3.5.1 with a p-value threshold of 0.05 on each set of raw expression measure. Subsequent
 359 bioinformatics analyses including Canonical Pathway Analysis and Regulator Effect Network Analysis

360 were performed using Ingenuity Pathway Analysis (IPA; Qiagen) for each time-point. All generated
361 sequence data have been submitted to Gene Expression Omnibus with accession number GSE168896.

362 Statistics

363 For statistical analyses, the non-parametric Kruskal-Wallis test, one-way ANOVA, repeated measures
364 two-way ANOVA, and unpaired student's t-test were utilized to assess significance between
365 experimental groups. Data were presented as mean $\pm$ standard deviation. A *p* value less than 0.05 was
366 considered significant.

367 **Acknowledgments**

368 The authors would also like to thank Drs. Chad Galloway and Elysia A. Masters for their technical
369 assistance. The authors would like to thank the Electron Microscope Shared Resource Laboratory,
370 Genomics Research Center, and the Histology, Biochemistry, and Molecular Imaging Core in the Center
371 for Musculoskeletal Research at the University of Rochester Medical Center.

372

373 **Funding**

374 This work was supported by NIH NIAMS P30 AR069655 pilot grant (GM) with additional support from
375 NIH NIAMS P50 AR072000 (EMS), P30 AR069655 (EMS), and AO Trauma Clinical Priority Program
376 (EMS, SLK).

377

378 **Conflict of interest statement**

379 The authors have declared that no conflict of interest exists.

380

381 **Data availability**

382 All RNA sequence data have been submitted to the Gene Expression Omnibus with accession number
383 GSE168896.

384 References

- 385 1. Schwarz EM, Parvizi J, Gehrke T, Aiyer A, Battenberg A, Brown SA, et al. 2018 International
386 Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly
387 Questions. *J Orthop Res*. 2019;37(5):997-1006. Epub 2019/04/13. doi: 10.1002/jor.24293. PubMed
388 PMID: 30977537.
- 389 2. Tande AJ, Patel R. Prosthetic joint infection. *Clin Microbiol Rev*. 2014;27(2):302-45. Epub
390 2014/04/04. doi: 10.1128/CMR.00111-13. PubMed PMID: 24696437; PubMed Central PMCID:
391 PMCPMC3993098.
- 392 3. Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM. Adherence to surgical
393 care improvement project measures and the association with postoperative infections. *Jama*.
394 2010;303(24):2479-85. Epub 2010/06/24. doi: 10.1001/jama.2010.841. PubMed PMID: 20571014.
- 395 4. Kates SL, Tornetta P, 3rd. Commentary on Secondary Fracture Prevention: Consensus Clinical
396 Recommendations From a Multistakeholder Coalition Originally Published in the *Journal of Bone and*
397 *Mineral Research*. *J Orthop Trauma*. 2020;34(4):221. Epub 2020/03/21. doi:
398 10.1097/BOT.0000000000001742. PubMed PMID: 32195890.
- 399 5. Goodson KM, Kee JR, Edwards PK, Novack AJ, Stambough JB, Siegel ER, et al. Streamlining
400 Hospital Treatment of Prosthetic Joint Infection. *J Arthroplasty*. 2020;35(3S):S63-S8. Epub 2020/02/13.
401 doi: 10.1016/j.arth.2019.10.056. PubMed PMID: 32046835.
- 402 6. Depypere M, Morgenstern M, Kuehl R, Senneville E, Moriarty TF, Obremskey WT, et al.
403 Pathogenesis and management of fracture-related infection. *Clin Microbiol Infect*. 2020;26(5):572-8.
404 Epub 2019/08/26. doi: 10.1016/j.cmi.2019.08.006. PubMed PMID: 31446152.
- 405 7. Govaert GAM, Kuehl R, Atkins BL, Trampuz A, Morgenstern M, Obremskey WT, et al.
406 Diagnosing Fracture-Related Infection: Current Concepts and Recommendations. *J Orthop Trauma*.
407 2020;34(1):8-17. Epub 2019/12/20. doi: 10.1097/BOT.0000000000001614. PubMed PMID: 31855973;
408 PubMed Central PMCID: PMC6903359.
- 409 8. Kandel CE, Jenkinson R, Daneman N, Backstein D, Hansen BE, Muller MP, et al. Predictors of
410 Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage
411 Exchange Arthroplasty: A Multicenter Retrospective Cohort. *Open Forum Infect Dis*.
412 2019;6(11):ofz452. Epub 2019/11/19. doi: 10.1093/ofid/ofz452. PubMed PMID: 31737739; PubMed
413 Central PMCID: PMC6847009.
- 414 9. Masters EA, Trombetta RP, de Mesy Bentley KL, Boyce BF, Gill AL, Gill SR, et al. Evolving
415 concepts in bone infection: redefining "biofilm", "acute vs. chronic osteomyelitis", "the immune
416 proteome" and "local antibiotic therapy". *Bone Res*. 2019;7:20. doi: 10.1038/s41413-019-0061-z.
417 PubMed PMID: 31646012; PubMed Central PMCID: PMC6804538.
- 418 10. Kaplan SL. Recent lessons for the management of bone and joint infections. *J Infect*. 2014;68
419 Suppl 1:S51-6. Epub 2013/10/15. doi: 10.1016/j.jinf.2013.09.014. PubMed PMID: 24119927.
- 420 11. Assis LM, Nedeljkovic M, Dessen A. New strategies for targeting and treatment of multi-drug
421 resistant *Staphylococcus aureus*. *Drug Resist Updat*. 2017;31:1-14. Epub 2017/09/05. doi:
422 10.1016/j.drug.2017.03.001. PubMed PMID: 28867240.
- 423 12. Weigelt JA, Lipsky BA, Tabak YP, Derby KG, Kim M, Gupta V. Surgical site infections:
424 Causative pathogens and associated outcomes. *Am J Infect Control*. 2010;38(2):112-20. Epub
425 2009/11/06. doi: 10.1016/j.ajic.2009.06.010. PubMed PMID: 19889474.
- 426 13. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of
427 mortality in *Staphylococcus aureus* Bacteremia. *Clinical microbiology reviews*. 2012;25(2):362-86.
428 Epub 2012/04/12. doi: 10.1128/CMR.05022-11. PubMed PMID: 22491776; PubMed Central PMCID:
429 PMC63346297.

- 430 14. Wong HR, Lindsell CJ, Lahni P, Hart KW, Gibot S. Interleukin 27 as a sepsis diagnostic
431 biomarker in critically ill adults. *Shock*. 2013;40(5):382-6. doi: 10.1097/SHK.0b013e3182a67632.
432 PubMed PMID: 23903853; PubMed Central PMCID: PMC3800476.
- 433 15. Wong HR, Liu KD, Kangelaris KN, Lahni P, Calfee CS. Performance of interleukin-27 as a
434 sepsis diagnostic biomarker in critically ill adults. *J Crit Care*. 2014;29(5):718-22. doi:
435 10.1016/j.jcrc.2014.04.004. PubMed PMID: 24848949; PubMed Central PMCID: PMC4141017.
- 436 16. Hanna WJ, Berrens Z, Langner T, Lahni P, Wong HR. Interleukin-27: a novel biomarker in
437 predicting bacterial infection among the critically ill. *Crit Care*. 2015;19:378. doi: 10.1186/s13054-015-
438 1095-2. PubMed PMID: 26514771; PubMed Central PMCID: PMC4627377.
- 439 17. He Y, Du WX, Jiang HY, Ai Q, Feng J, Liu Z, et al. Multiplex Cytokine Profiling Identifies
440 Interleukin-27 as a Novel Biomarker For Neonatal Early Onset Sepsis. *Shock*. 2017;47(2):140-7. doi:
441 10.1097/SHK.0000000000000753. PubMed PMID: 27648693.
- 442 18. Jacobs L, Berrens Z, Stenson EK, Zackoff M, Danziger-Isakov L, Lahni P, et al. Interleukin-27
443 as a candidate diagnostic biomarker for bacterial infection in immunocompromised pediatric patients.
444 *PLoS One*. 2018;13(11):e0207620. doi: 10.1371/journal.pone.0207620. PubMed PMID: 30475852;
445 PubMed Central PMCID: PMC6261028.
- 446 19. Wong HR CN, Hall M, Allen GL, Thomas NJ, Freishtat RJ, Anas N, Meyer K, Checchia PA,
447 Lin R, Bigham MT, Sen A, Nowak J, Quasney M, Henricksen JW, Chopra A, Banschbach S, Beckman
448 E, Harmon K, Lahni P, Shanley TP. Interleukin-27 is a novel candidate diagnostic biomarker for
449 bacterial infection in critically ill children. *Crit Care*. 2012;16(5): R213. doi: 10.1186/cc11847.
- 450 20. Yoshida H, Hunter CA. The immunobiology of interleukin-27. *Annu Rev Immunol*.
451 2015;33:417-43. Epub 2015/04/12. doi: 10.1146/annurev-immunol-032414-112134. PubMed PMID:
452 25861977.
- 453 21. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions.
454 *Nature reviews Immunology*. 2005;5(7):521-31. Epub 2005/07/07. doi: 10.1038/nri1648. PubMed
455 PMID: 15999093.
- 456 22. Pflanz S TJ, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L,, Churakova T TM, Vaisberg
457 E, Blumenschein WM, Mattson JD, Wagner JL, To W, , Zurawski S MT, Gorman DM, Bazan JF, de
458 Waal Malefyt R, Rennick D,, RA. K. IL-27, a heterodimeric cytokine composed of EB13 and p28
459 protein, induces proliferation of naive CD4+ T cells. *Immunity*. 2002;16(6):779-90. doi: 10.1016/s1074-
460 7613(02)00324-2
- 461 23. Morita YM, E.A.; Schwarz, E.M.; Muthukrishnan G. Interleukin-27 and its diverse effects on
462 bacterial infections. *Frontiers in Immunology*. 2021;(In press).
- 463 24. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27
464 blocks RORc expression to inhibit lineage commitment of Th17 cells. *J Immunol*. 2009;182(9):5748-56.
465 Epub 2009/04/22. doi: 10.4049/jimmunol.0801162. PubMed PMID: 19380822.
- 466 25. Hall AO, Beiting DP, Tato C, John B, Oldenhove G, Lombana CG, et al. The cytokines
467 interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-
468 induced pathology. *Immunity*. 2012;37(3):511-23. Epub 2012/09/18. doi:
469 10.1016/j.immuni.2012.06.014. PubMed PMID: 22981537; PubMed Central PMCID:
470 PMC3477519.
- 471 26. Cao J, Xu F, Lin S, Song Z, Zhang L, Luo P, et al. IL-27 controls sepsis-induced impairment of
472 lung antibacterial host defence. *Thorax*. 2014;69(10):926-37. Epub 2014/07/31. doi: 10.1136/thoraxjnl-
473 2014-205777. PubMed PMID: 25074706.
- 474 27. Robinson KM, Lee B, Scheller EV, Mandalapu S, Enelow RI, Kolls JK, et al. The role of IL-27
475 in susceptibility to post-influenza *Staphylococcus aureus* pneumonia. *Respir Res*. 2015;16:10. Epub
476 2015/02/06. doi: 10.1186/s12931-015-0168-8. PubMed PMID: 25651926; PubMed Central PMCID:
477 PMC4324414.

28. Seita J, Asakawa M, Ooehara J, Takayanagi S, Morita Y, Watanabe N, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. *Blood*. 2008;111(4):1903-12. doi: 10.1182/blood-2007-06-093328. PubMed PMID: 18042804.
29. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. *J Immunol*. 2004;172(4):2225-31. doi: 10.4049/jimmunol.172.4.2225. PubMed PMID: 14764690.
30. Guzzo C, Che Mat NF, Gee K. Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. *J Biol Chem*. 2010;285(32):24404-11. doi: 10.1074/jbc.M110.112599. PubMed PMID: 20519510; PubMed Central PMCID: PMC2915676.
31. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. *Proc Natl Acad Sci U S A*. 2003;100(25):15047-52. doi: 10.1073/pnas.2536517100. PubMed PMID: 14657353; PubMed Central PMCID: PMC299900.
32. Nishitani K, Sutipornpalangkul W, de Mesy Bentley KL, Varrone JJ, Bello-Irizarry SN, Ito H, et al. Quantifying the natural history of biofilm formation in vivo during the establishment of chronic implant-associated *Staphylococcus aureus* osteomyelitis in mice to identify critical pathogen and host factors. *J Orthop Res*. 2015;33(9):1311-9. doi: 10.1002/jor.22907. PubMed PMID: 25820925; PubMed Central PMCID: PMC4529770.
33. Masters EA, de Mesy Bentley KL, Gill AL, Hao SP, Galloway CA, Salminen AT, et al. Identification of Penicillin Binding Protein 4 (PBP4) as a critical factor for *Staphylococcus aureus* bone invasion during osteomyelitis in mice. *PLoS Pathog*. 2020;16(10):e1008988. doi: 10.1371/journal.ppat.1008988. PubMed PMID: 33091079; PubMed Central PMCID: PMC7608983 silicon-based technologies.
34. Nishitani K, Ishikawa M, Morita Y, Yokogawa N, Xie C, de Mesy Bentley KL, et al. IsdB antibody-mediated sepsis following *S. aureus* surgical site infection. *JCI Insight*. 2020;5(19). doi: 10.1172/jci.insight.141164. PubMed PMID: 33004694; PubMed Central PMCID: PMC7566716.
35. Masters EA, Hao SP, Kenney HM, Morita Y, Galloway CA, de Mesy Bentley KL, et al. Distinct vasculotropic versus osteotropic features of *S. agalactiae* versus *S. aureus* implant-associated bone infection in mice. *J Orthop Res*. 2021;39(2):389-401. doi: 10.1002/jor.24962. PubMed PMID: 33336806.
36. Varrone JJ, de Mesy Bentley KL, Bello-Irizarry SN, Nishitani K, Mack S, Hunter JG, et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of *Staphylococcus aureus* megaclusters. *J Orthop Res*. 2014;32(10):1389-96. doi: 10.1002/jor.22672. PubMed PMID: 24992290; PubMed Central PMCID: PMC4234088.
37. Frangieh M, McHenry A, Phillips R, Ye C, Bernier A, Laffel L, et al. IL-27: An endogenous constitutive repressor of human monocytes. *Clin Immunol*. 2020;217:108498. doi: 10.1016/j.clim.2020.108498. PubMed PMID: 32531345.
38. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell*. 2006;126(6):1121-33. doi: 10.1016/j.cell.2006.07.035. PubMed PMID: 16990136.
39. Fan J, Zhang YC, Zheng DF, Zhang M, Liu H, He M, et al. IL-27 is elevated in sepsis with acute hepatic injury and promotes hepatic damage and inflammation in the CLP model. *Cytokine*. 2020;127:154936. doi: 10.1016/j.cyto.2019.154936. PubMed PMID: 31786500.
40. Muthukrishnan G, Masters EA, Daiss JL, Schwarz EM. Mechanisms of Immune Evasion and Bone Tissue Colonization That Make *Staphylococcus aureus* the Primary Pathogen in Osteomyelitis. *Curr Osteoporos Rep*. 2019. Epub 2019/11/14. doi: 10.1007/s11914-019-00548-4. PubMed PMID: 31721069.

41. Wang L, Cao J, Li C, Zhang L. IL-27/IL-27 Receptor Signaling Provides Protection in Clostridium difficile-Induced Colitis. *J Infect Dis*. 2018;217(2):198-207. doi: 10.1093/infdis/jix581. PubMed PMID: 29140433.
42. Gao F, Yang YZ, Feng XY, Fan TT, Jiang L, Guo R, et al. Interleukin-27 is elevated in sepsis-induced myocardial dysfunction and mediates inflammation. *Cytokine*. 2016;88:1-11. doi: 10.1016/j.cyto.2016.08.006. PubMed PMID: 27525353.
43. Lin Y, Su J, Wang Y, Xu D, Zhang X, Yu B. mRNA transcriptome analysis of bone in a mouse model of implant-associated Staphylococcus aureus osteomyelitis. *Infect Immun*. 2021. doi: 10.1128/IAI.00814-20. PubMed PMID: 33619031.
44. Milner JD, Brechley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. *Nature*. 2008;452(7188):773-6. doi: 10.1038/nature06764. PubMed PMID: 18337720; PubMed Central PMCID: PMC2864108.
45. Marques JM, Rial A, Munoz N, Pellay FX, Van Maele L, Leger H, et al. Protection against Streptococcus pneumoniae serotype 1 acute infection shows a signature of Th17- and IFN-gamma-mediated immunity. *Immunobiology*. 2012;217(4):420-9. doi: 10.1016/j.imbio.2011.10.012. PubMed PMID: 22204818.
46. Lubberts E KM, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. *Arthritis Res Ther*. 2005;7(1):29-37. doi: 10.1186/ar1478).
47. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. *J Clin Immunol*. 2010;30(1):80-9. doi: 10.1007/s10875-009-9345-1. PubMed PMID: 19936899.
48. Roeleveld DM, Koenders MI. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. *Cytokine*. 2015;74(1):101-7. doi: 10.1016/j.cyto.2014.10.006. PubMed PMID: 25466295.
49. Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, et al. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. *J Bone Miner Metab*. 2007;25(5):277-85. doi: 10.1007/s00774-007-0766-8. PubMed PMID: 17704992.
50. Shukla P, Mansoori MN, Kakaji M, Shukla M, Gupta SK, Singh D. Interleukin 27 (IL-27) Alleviates Bone Loss in Estrogen-deficient Conditions by Induction of Early Growth Response-2 Gene. *J Biol Chem*. 2017;292(11):4686-99. doi: 10.1074/jbc.M116.764779. PubMed PMID: 28130449; PubMed Central PMCID: PMC5377783.
51. Li X LW, Hu J, Chen Y, Yu T, Yang J, Dong S, Tian X, Sun L. Interleukin-27 prevents LPS-induced inflammatory osteolysis by inhibiting osteoclast formation and function. *Am J Transl Res*. 2019;11(3):1154-1169.; PubMed Central PMCID: PMC6456512.
52. Terkawi MA, Kadoya K, Takahashi D, Tian Y, Hamasaki M, Matsumae G, et al. Identification of IL-27 as potent regulator of inflammatory osteolysis associated with vitamin E-blended ultra-high molecular weight polyethylene debris of orthopedic implants. *Acta Biomater*. 2019;89:242-51. doi: 10.1016/j.actbio.2019.03.028. PubMed PMID: 30880234.
53. Holscher C, Holscher A, Ruckerl D, Yoshimoto T, Yoshida H, Mak T, et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. *J Immunol*. 2005;174(6):3534-44. doi: 10.4049/jimmunol.174.6.3534. PubMed PMID: 15749890.
54. Owaki T, Asakawa M, Kamiya S, Takeda K, Fukai F, Mizuguchi J, et al. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. *J Immunol*. 2006;176(5):2773-80. doi: 10.4049/jimmunol.176.5.2773. PubMed PMID: 16493033.
55. Karakhanova S, Bedke T, Enk AH, Mahnke K. IL-27 renders DC immunosuppressive by induction of B7-H1. *J Leukoc Biol*. 2011;89(6):837-45. doi: 10.1189/jlb.1209788. PubMed PMID: 21345970.

56. Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naive CD8⁺ T lymphocytes and promotes their development into Tc1 cells. *Eur J Immunol.* 2011;41(1):47-59. doi: 10.1002/eji.201040804. PubMed PMID: 21182076.

57. Petes C, Odoardi N, Plater SM, Martin NL, Gee K. IL-27 amplifies cytokine responses to Gram-negative bacterial products and *Salmonella typhimurium* infection. *Sci Rep.* 2018;8(1):13704. doi: 10.1038/s41598-018-32007-y. PubMed PMID: 30209294; PubMed Central PMCID: PMC6135775.

58. Choi YH, Lim EJ, Kim SW, Moon YW, Park KS, An HJ. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells. *J Immunother Cancer.* 2019;7(1):168. doi: 10.1186/s40425-019-0652-7. PubMed PMID: 31277710; PubMed Central PMCID: PMC6612093.

59. Muthukrishnan G, Wallimann A, Rangel-Moreno J, Bentley KLdM, Hildebrand M, Mys K, et al. Humanized Mice Exhibit Exacerbated Abscess Formation and Osteolysis During the Establishment of Implant-Associated *Staphylococcus aureus* Osteomyelitis. *Frontiers in Immunology.* 2021;12(809). doi: 10.3389/fimmu.2021.651515.

60. Morgenstern M, Erichsen C, Militz M, Xie Z, Peng J, Stannard J, et al. The AO trauma CPP bone infection registry: Epidemiology and outcomes of *Staphylococcus aureus* bone infection. *J Orthop Res.* 2020. Epub 2020/07/29. doi: 10.1002/jor.24804. PubMed PMID: 32720352.

61. Murray PJ AJ, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity.* 2014;41(1):14-20. doi: 10.1016/j.immuni.2014.06.008.

62. Lu SC, Wu HW, Lin YJ, Chang SF. The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. *Am J Physiol Cell Physiol.* 2009;296(5):C1133-9. doi: 10.1152/ajpcell.00031.2009. PubMed PMID: 19279235.

63. Fang FC, Vazquez-Torres A. Reactive nitrogen species in host-bacterial interactions. *Curr Opin Immunol.* 2019;60:96-102. doi: 10.1016/j.coi.2019.05.008. PubMed PMID: 31200187; PubMed Central PMCID: PMC6800629.

64. Zhu X, Liu Z, Liu JQ, Zhu J, Zhang J, Davis JP, et al. Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells. *J Leukoc Biol.* 2016;100(2):403-11. Epub 2016/04/24. doi: 10.1189/jlb.3A1215-540R. PubMed PMID: 27106672; PubMed Central PMCID: PMC64945352.

65. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics.* 2018;34(17):i884-i90. doi: 10.1093/bioinformatics/bty560. PubMed PMID: 30423086; PubMed Central PMCID: PMC6129281.

66. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29(1):15-21. doi: 10.1093/bioinformatics/bts635. PubMed PMID: 23104886; PubMed Central PMCID: PMC3530905.

67. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res.* 2013;41(10):e108. doi: 10.1093/nar/gkt214. PubMed PMID: 23558742; PubMed Central PMCID: PMC3664803.

68. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed PMID: 25516281; PubMed Central PMCID: PMC4302049.

620 **Table 1. In vitro cytokine assay with *S. aureus* infected murine bone marrow derived macrophages**
621 **in the presence or absence of IL-27**

	PBS+<i>S.aureus</i> infection			IL-27+<i>S.aureus</i> infection		
IL-1β	99.1	$\pm$	28.7	90.8	$\pm$	14.4
IL-2	144.9	$\pm$	2.2	155.2	$\pm$	8.7
IL-4	168.0	$\pm$	3.3	174.5	$\pm$	7.9
IL-5	518.8	$\pm$	9.9	554.4	$\pm$	31.2
IL-6	12595.4	$\pm$	1263.0	10174.4	$\pm$	2138.8
IL-10	3721.7	$\pm$	27.0	3915.8	$\pm$	129.7*
IL-13	1354.3	$\pm$	28.2	1397.1	$\pm$	141.8
IL-15	41387.8	$\pm$	1327.2	42200.2	$\pm$	2124.3
IL-17A	747.3	$\pm$	60.4	778.3	$\pm$	61.0
IL-17F	1079.8	$\pm$	19.1	1099.1	$\pm$	64.1
IL-21	2279.2	$\pm$	91.6	2439.9	$\pm$	20.0*
IL-22	1827.6	$\pm$	61.4	1859.3	$\pm$	84.1
IL-23	7492.5	$\pm$	182.3	8042.7	$\pm$	142.0
IL-31	2454.4	$\pm$	94.1	2672.7	$\pm$	25.3**
IL-33	10965.5	$\pm$	125.8	11595.4	$\pm$	701.2
IFN-γ	164.3	$\pm$	3.5	167.5	$\pm$	8.8
IFN-λ3/IL-28B	472.9	$\pm$	13.8	488.4	$\pm$	37.1
TNF-α	500.2	$\pm$	24.4	482.7	$\pm$	9.5
TNF-β	87365.0	$\pm$	1032.4	99471.3	$\pm$	5440.6**
GM-CSF	265.0	$\pm$	11.1	281.4	$\pm$	6.9
MIP-3a/CCL20	5648.3	$\pm$	247.4	5670.9	$\pm$	37.3
CD40L	9229.2	$\pm$	87.6	9870.0	$\pm$	487.6

622 Data are presented mean $\pm$ SD (pg/mL) (N=3, *p<0.05, **p< 0.01, one-way ANOVA)
623

624 **Figure Legends**

625 **Figure 1. IL-27 levels are elevated in patients and in mice with *S. aureus* infection. A)** Serum
 626 samples were collected from healthy people (n=10), orthopaedic patients with culture confirmed *S.*
 627 *aureus* bone infections (n=23), and patients who died from septic *S. aureus* osteomyelitis (n=5). Serum
 628 IL-27 levels were determined via Luminex assay, and the data for each sample is presented with the
 629 mean +/- SEM for the group. **B)** The Luminex data were utilized to perform a receiver operating
 630 characteristic (ROC) curve, and the area under the curve (AUC) between controls and infected patients
 631 is presented. Note that serum IL-27 levels are highly diagnostic of *S. aureus* osteomyelitis. The dashed
 632 line represents a non-discriminatory test with equal sensitivity and specificity. In vitro cultures of **(C)**
 633 RAW264.7 cells and **(D)** primary murine bone marrow-derived macrophages were differentiated with
 634 PBS, IFN- γ (50ng/ml) or IL-4 (20ng/ml) to generate M0, M1 and M2 cells respectively, and then
 635 exposed to *S. aureus* USA300 (MOI = 10). These cultures were incubated for 24 hours, and IL-27 levels
 636 in the supernatants were assessed via ELISA. The data from each experiment are presented with the
 637 mean +/- SD for the group (n=3) (* p <0.05, ** p <0.01, *** p <0.001 **** p <0.0001, ANOVA).

639 **Figure 2. Systemic IL-27 ameliorates surgical site soft tissue infection and osteolysis during *S.***
 640 ***aureus* implant-associated osteomyelitis. (A)** 8-week-old female C57BL/6 mice received 0.5×10^{12}
 641 genome copies/mouse of rAAV-IL-27 (n=3) or rAAV-GFP (control, n=5) via intramuscular injection,
 642 and serum samples were collected longitudinally to assess IL-27 levels via ELISA. Exogenous IL-27
 643 levels in sera are presented as the mean +/- SD. **(B-F)** A separate cohort of these mice were
 644 intramuscularly injected with rAAV-IL-27 or rAAV-GFP (n=16), and then challenged 7 days later with
 645 5×10^5 CFU of USA300 LAC::lux on a contaminated transtibial pin as described in Materials and
 646 Methods. Longitudinal BLI **(B)** and animal weight **(C)** were obtained on days 0, 1, 3, 7, 10 & 14, and
 647 the data are presented as the mean +/- SD (* p <0.05 on Day 3, *** p <0.001 on Day 10 and 14, two-way
 648 ANOVA). **(D)** Photographs of the infected tibiae were obtained on day 14, and representative images of

649 the large vs. small draining abscesses observed in the rAAV-GFP and rAAV-IL-27 treated mice
650 respectively are shown. The mice were euthanized on day 14, and the infected tibiae were harvested for
651 CFU and micro-CT analyses. **(E)** CFUs from the implant, soft tissue and tibia were determined, and the
652 data for each tibia are presented with the mean +/- SD for the group (n=10, **** $p < 0.0001$, t test). **(F)**
653 Representative 3D renderings of the extensive peri-implant osteolysis and reactive bone formation in
654 rAAV-GFP vs. rAAV-IL-27 treated tibiae are shown with the volumetric bone loss in the infected tibiae.
655 Data are presented for each tibia with the mean +/- SD for the group (n=6, * $p < 0.05$, t test).

656

657 **Figure 3. Absence of systemic IL-27 effects on implant associated osteomyelitis in IL-27R α ^{-/-} mice.**
658 Female IL-27R α ^{-/-} mice (C57BL/6 background) were intramuscularly injected with rAAV-IL-27 or
659 rAAV- GFP and then challenged with a MRSA (USA300 LAC::lux) contaminated transtibial implant as
660 described in Figure 2. Animal weight **(A)** and BLI **(B)** were obtained on days 0, 1, 3, 7, 10 & 14, and the
661 data are presented as the mean +/- SD for the group (n=5). **(C)** Representative photographs obtained on
662 day 14 post-surgery, illustrate similar large draining abscesses in both groups. **(D)** CFUs from the
663 implant, surgical site soft tissue, and tibia were determined after euthanasia on day 14 post-op, and data
664 from each tibia are presented with the mean +/- SD for the group (n=5). No differences were observed
665 between the experimental groups.

666

667 **Figure 4. Identification of systemic IL-27 affected pathways during the establishment of implant-**
668 **associated osteomyelitis via bulk RNA sequencing of *S. aureus*-infected tibia. (A)** MRSA-infected
669 tibiae were collected on days 1, 3, 7 and 14 post-septic surgery for bulk RNA sequencing (n=3), and
670 differential gene expression between rAAV-IL-27 and rAAV-GFP treated mice were evaluated using
671 DESeq2-1.22.1 R/Bioconductor package. **(B)** The number of significant differentially up-regulated and
672 down-regulated genes in mice treated with rAAV-IL-27 on each day is shown. **(C)** Expression of *IL27*
673 in infected tibiae was upregulated in mice treated with rAAV-IL-27, suggesting a positive feedback

effect. (**** $p < 0.0001$ on days 1 & 3, *** $p < 0.001$ on days 7 & 14). (D) Venn diagram analyses showing the overlap of DEGs across days 1, 3, 7 and 14 post-septic surgery in mice treated with rAAV-IL-27 vs. rAAV-GFP, respectively. (E) Ingenuity Pathway Analysis (IPA) was utilized to identify canonical pathways of DEGs between rAAV-IL-27 vs. rAAV-GFP treated mice over time. Significant association ($p < 0.05$) were calculated based on the Fisher's right tailed exact test. The orange and blue colored bars indicate predicted pathway activation or predicted pathway suppression in mice treated with rAAV-IL-27 vs. rAAV-GFP respectively (z-score). White bars indicate z-score at or very close to 0. Some pro-inflammatory/immune pathways including IL-17 signaling, Th17 activating pathway, IL-2 signaling were activated in mice treated with rAAV-IL-27 on day 1 following infection. On the other hand, these pathways and others (e.g.) were estimated to be suppressed at later time points. Moreover, immunosuppressive PD-1/PD-L1 signaling pathway was upregulated at later time points. These results indicate that IL-27 is a biphasic cytokine that activates pro-inflammatory/immune pathways early upon *S. aureus* infection, and then suppresses them late to prevent tissue damage and cytokine storm.

Figure 5. IL-27 up-regulated pro-inflammatory cytokines during the initiation of implant-associated *S. aureus* osteomyelitis and their down-regulation during chronic infection. DEGs in the (A) IL-23, (B) Th17, (C) TLR, and (D) iNOS signaling pathways are shown with log₂ fold change on each day as heatmaps. The orange and blue colored bars indicate up-regulation or down-regulation in mice treated with rAAV-IL-27 vs. rAAV-GFP, respectively (log₂ fold change, $p < 0.05$). Pro-inflammatory cytokine coding genes such as *IL17A*, *IL17F*, *IL21*, and *IL12B* were upregulated on day-1 post-surgery. In contrast, pro-inflammatory cytokine genes such as *IL17A*, *IL12A*, *TNF*, and *IL6* were downregulated on day-14.

Figure 6. Systemic IL-27 inhibits osteoclast formation during implant-associated osteomyelitis. (A) Data from the IPA in Figure 4 are shown to illustrate the decrease in RANK signaling in rAAV-IL27 vs.

699 rAAV-GFP treated infected tibiae on days 3, 7 and 14. **(B)** To confirm the gene expression data, tibiae
700 from the mice described Figure 2 were processed for histology. Representative 2x images of tibia
701 sections stained for TRAP (red/purple) are shown (scale bars = 500 μ m). **(C)** % TRAP-stained area was
702 quantified within the cortical bone regions, trabecular bone regions, and implant sites (red box), and the
703 data are presented for each tibia with the mean +/- SD for the group (n=6, ** p <0.05, t test).

704
705 **Figure 7. Schematic model of IL-27 mediated immune homeostasis during *S. aureus* osteomyelitis.**

706 Here, we propose a model of IL-27-mediated immune homeostasis during *S. aureus* osteomyelitis in
707 which IL-27 promotes host immune reaction against *S. aureus* osteomyelitis by regulating its reported
708 diverse immune-activation and immune-suppression effects in a time dependent manner. **(A)** At the
709 onset of *S. aureus* osteomyelitis, IL-27 promotes production of pro-inflammatory cytokines, leading to
710 enhanced bacteria killing by macrophages and neutrophils. **(B)** In contrast, at later stages of *S. aureus*
711 osteomyelitis following acute reaction, IL-27 decreases production of pro-inflammatory cytokines and
712 osteoclastogenesis, which prevents cytokine storm and osteolysis.

713
714 **Supplemental Figure 1. Systemic IL-27 does not affect biofilm formation on the implant during *S.***

715 ***aureus* implant-associated osteomyelitis in vivo.** Mice were intramuscularly injected with rAAV-IL-
716 27 or rAAV-GFP and then challenged with a MRSA (USA300 LAC::lux) contaminated transtibial
717 implant as described in Figure 2. Biofilm formation on the implant was determined via SEM processing
718 and imaging after euthanasia on day 14 post-op. No difference was detected in %biofilm formation area
719 on implant between rAAV-IL-27 and rAAV-GFP challenged mice (n=6).

720
721 **Supplemental Figure 2. IL-27 does not stimulate myeloid cell chemotaxis.** HL-60 cells were
722 differentiated 7 days in the presence or absence of dimethylformamide (DMF) (9 μ g/ml), and then
723 placed in Boyden chambers. Cell culture media with or without IL-27 or fMLP (positive-control) was

placed in the well below the chamber and incubated for 1 hour. Subsequently, cells which migrated in each well were stained with fluorescent dye and signal intensity was evaluated using a fluorescent plate reader (n=2). No difference in chemotactic activity of granulocytes was observed between the experimental groups.

Supplemental Figure 3. IL-27 enhances LPS-induced NO⁻ production by macrophage cultures.

Primary bone marrow derived murine macrophages were pretreated with PBS or IL-27 (50 ng/ml) for 24 hours, and then stimulated with LPS (100 ng/ml) in the presence or absence of IL-27 (50 ng/ml) for 24 hours. Nitrite levels in the culture supernatant was determined via Griess reaction assay, and the data from each experiment are presented with the mean +/- SD for the group (n=3, * p <0.05, ** p <0.01, *** p <0.0001 by one-way ANOVA).

Figure 1

Figure 1. IL-27 levels are elevated in patients and in mice with *S. aureus* infection. **A)** Serum samples were collected from healthy people (n=10), orthopaedic patients with culture confirmed *S. aureus* bone infections (n=23), and patients who died from septic *S. aureus* osteomyelitis (n=5). Serum IL-27 levels were determined via Luminex assay, and the data for each sample is presented with the mean $\pm$ SEM for the group. **B)** The Luminex data were utilized to perform a receiver operating characteristic (ROC) curve, and the area under the curve (AUC) between controls and infected patients is presented. Note that serum IL-27 levels are highly diagnostic of *S. aureus* osteomyelitis. The dashed line represents a non-discriminatory test with equal sensitivity and specificity. In vitro cultures of **(C)** RAW264.7 cells and **(D)** primary murine bone marrow-derived macrophages were differentiated with PBS, IFN- γ (50ng/ml) or IL-4 (20ng/ml) to generate M0, M1 and M2 cells respectively, and then exposed to *S. aureus* USA300 (MOI = 10). These cultures were incubated for 24 hours, and IL-27 levels in the supernatants were assessed via ELISA. The data from each experiment are presented with the mean $\pm$ SD for the group (n=3) (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, ANOVA).

Figure 2

Figure 2. Systemic IL-27 ameliorates surgical site soft tissue infection and osteolysis during *S. aureus* implant-associated osteomyelitis. (A) 8-week-old female C57BL/6 mice received 0.5×10^{12} genome copies/mouse of rAAV-IL-27 (n=3) or rAAV-GFP (control, n=5) via intramuscular injection, and serum samples were collected longitudinally to assess IL-27 levels via ELISA. Exogenous IL-27 levels in sera are presented as the mean $\pm$ SD. (B-F) A separate cohort of these mice were intramuscularly injected with rAAV-IL-27 or rAAV-GFP (n=16), and then challenged 7 days later with 5×10^5 CFU of USA300 LAC::lux on a contaminated transtibial pin as described in Materials and Methods. Longitudinal BLI (B) and animal weight (C) were obtained on days 0, 1, 3, 7, 10 & 14, and the data are presented as the mean $\pm$ SD (* p < 0.05 on Day 3, *** p < 0.001 on Day 10 and 14, two-way ANOVA). (D) Photographs of the infected tibiae were obtained on day 14, and representative images of the large vs. small draining abscesses observed in the rAAV-GFP and rAAV-IL-27 treated mice respectively are shown. The mice were euthanized on day 14, and the infected tibiae were harvested for CFU and micro-CT analyses. (E) CFUs from the implant, soft tissue and tibia were determined, and the data for each tibia are presented with the mean $\pm$ SD for the group (n=10, **** p < 0.0001, t test). (F) Representative 3D renderings of the extensive peri-implant osteolysis and reactive bone formation in rAAV-GFP vs. rAAV-IL-27 treated tibiae are shown with the volumetric bone loss in the infected tibiae. Data are presented for each tibia with the mean $\pm$ SD for the group (n=6, * p < 0.05, t test).

Figure 3

Figure 3. Absence of systemic IL-27 effects on implant associated osteomyelitis in IL-27R α ^{-/-} mice. Female IL-27R α ^{-/-} mice (C57BL/6 background) were intramuscularly injected with rAAV-IL-27 or rAAV-GFP and then challenged with a MRSA (USA300 LAC::lux) contaminated transtibial implant as described in Figure 2. Animal weight (A) and BLI (B) were obtained on days 0, 1, 3, 7, 10 & 14, and the data are presented as the mean $\pm$ SD for the group (n=5). (C) Representative photographs obtained on day 14 post-surgery, illustrate similar large draining abscesses in both groups. (D) CFUs from the implant, surgical site soft tissue, and tibia were determined after euthanasia on day 14 post-op, and data from each tibia are presented with the mean $\pm$ SD for the group (n=5). No differences were observed between the experimental groups.

Figure 4

Figure 4. Identification of systemic IL-27 affected pathways during the establishment of implant-associated osteomyelitis via bulk RNA sequencing of *S. aureus*-infected tibia. (A) MRSA-infected tibiae were collected on days 1, 3, 7 and 14 post-septic surgery for bulk RNA sequencing (n=3), and differential gene expression between rAAV-IL-27 and rAAV-GFP treated mice were evaluated using DESeq2-1.22.1 R/Bioconductor package. (B) The number of significant differentially up-regulated and down-regulated genes in mice treated with rAAV-IL-27 on each day is shown. (C) Venn diagram analyses showing the overlap of DEGs across days 1, 3, 7 and 14 post-septic surgery in mice treated with rAAV-IL-27 vs. rAAV-GFP, respectively. (D) Expression of *IL27* in infected tibiae was upregulated in mice treated with rAAV-IL-27, suggesting a positive feedback effect. (**** $p < 0.0001$ on days 1 & 3, *** $p < 0.001$ on days 7 & 14). (E) Ingenuity Pathway Analysis (IPA) was utilized to identify canonical pathways of DEGs between rAAV-IL-27 vs. rAAV-GFP treated mice over time. Significant association ($*p < 0.05$) were calculated based on the Fisher's right tailed exact test. The orange and blue colored bars indicate predicted pathway activation or suppression in mice treated with rAAV-IL-27 vs. rAAV-GFP respectively (z-score). White bars indicate z-score at or very close to 0. Some pro-inflammatory/immune pathways including IL-17 signaling, Th17 activating pathway, IL-2 signaling were activated in mice treated with rAAV-IL-27 on day 1 following infection. On the other hand, these pathways and others (e.g.) were suppressed at later time points. Moreover, immunosuppressive PD-1/PD-L1 signaling pathway was upregulated at later time points. These result indicate that IL-27 is a biphasic cytokine that activates pro-inflammatory/immune pathways early upon *S. aureus* infection, and then suppresses them late to prevent tissue damage and cytokine storm.

Figure 5

Figure 5. IL-27 up-regulated pro-inflammatory cytokines during the initiation of implant-associated *S. aureus* osteomyelitis and their down-regulation during chronic infection. DEGs in the (A) IL-23, (B) Th17, (C) TLR, and (D) iNOS signaling pathways are shown with log₂ fold change on each day as heatmaps. The orange and blue colored bars indicate up-regulation or down-regulation in mice treated with rAAV-IL-27 vs. rAAV-GFP, respectively (log₂ fold change, $p < 0.05$). Pro-inflammatory cytokine coding genes such as *IL17A*, *IL17F*, *IL21*, and *IL12B* were upregulated on day-1 post-surgery. In contrast, pro-inflammatory cytokine genes such as *IL17A*, *IL12A*, *TNF*, and *IL6* were downregulated on day-14.

Figure 6

Figure 6. Systemic IL-27 inhibits osteoclast formation during implant-associated osteomyelitis. (A) Data from the IPA in Figure 4 are shown to illustrate the decrease in RANK signaling in rAAV-IL27 vs. rAAV-GFP treated infected tibiae on days 3, 7 and 14. **(B)** To confirm the gene expression data, tibiae from the mice described Figure 2 were processed for histology. Representative 2x images of tibia sections stained for TRAP (red/purple) are shown (scale bars = 500 μ m). **(C)** % TRAP-stained area was quantified within the cortical bone regions, trabecular bone regions, and implant sites (red box), and the data are presented for each tibia with the mean $\pm$ SD for the group (n=6, **p<0.05, t test).

Figure 7

Figure 7. Schematic model of IL-27 mediated immune regulation during *S. aureus* osteomyelitis. A schematic model of IL-27-mediated immune regulation during *S. aureus* osteomyelitis is shown in which IL-27 promotes host immune reaction against *S. aureus* osteomyelitis by regulating its reported diverse immune-activation and immune-suppression effects in a time dependent manner. **(A)** At the onset of *S. aureus* osteomyelitis, IL-27 promotes production of pro-inflammatory cytokines, leading to enhanced bacteria killing by macrophages and neutrophils. **(B)** In contrast, at later stages of *S. aureus* osteomyelitis following acute reaction, IL-27 decreases production of pro-inflammatory cytokines and osteoclastogenesis, which prevents cytokine storm and osteolysis.

Supplemental Figure 1

Supplemental Figure 1. Systemic IL-27 does not affect biofilm formation on the implant during *S. aureus* implant-associated osteomyelitis in vivo. Mice were intramuscularly injected with rAAV-IL-27 or rAAV-GFP and then challenged with a MRSA (USA300 LAC::lux) contaminated trans-tibial implant as described in Figure 2. Biofilm formation on the implant was determined via SEM processing and imaging after euthanasia on day 14 post-op. No difference was detected in %biofilm formation area on implant between rAAV-IL-27 and rAAV-GFP challenged mice (n=6).

Supplemental Figure 2. IL-27 does not stimulate myeloid cell chemotaxis. HL-60 cells were differentiated 7 days in the presence or absence of dimethylformamide (DMF) (9 μ g/ml), and then placed in Boyden chambers. Cell culture media with or without IL-27 or fMLP (positive-control) was placed in the well below the chamber and incubated for 1 hour. Subsequently, cells which migrated in each well were stained with fluorescent dye and signal intensity was evaluated using a fluorescent plate reader (n=2). No difference in chemotactic activity of granulocytes was observed between the experimental groups.

bioRxiv preprint doi: <https://doi.org/10.1101/2021.05.20.444931>; this version posted May 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Supplemental Figure 3. IL-27 enhances LPS-induced NO⁻ production by macrophage cultures. Primary bone marrow derived murine macrophages were pretreated with PBS or IL-27 (50 ng/ml) for 24 hours, and then stimulated with LPS (100 ng/ml) in the presence or absence of IL-27 (50 ng/ml) for 24 hours. Nitrite levels in the culture supernatant was determined via Griess reaction assay, and the data from each experiment are presented with the mean +/- SD for the group (n=3, *p<0.05, **p<0.01, ****p<0.0001 by one-way ANOVA).

Supplemental Table 1

Supplemental Table 1. Top regulatory effect networks of DEGs in mice treated with rAAV-IL-27 versus rAAV-GFP

		Consistency score	Regulators	Target molecules in dataset	Functions
Day 1	1	14.432	HSP90B1, HBB, EGR2, BCL2, TNFRSF4, LTA	BCL2A1, CXCL13, CCL20, CXCL9, CXCL6, IL7R, AIF1, IL21, IL17A, IL12B, VCAM1, IL17F, RORC, GZMB	Inflammation of body cavity, Inflammation of organ, Inflammation of absolute anatomical region, Inflammation of respiratory system component: Predicted activation
	2	8.05	NR1H	IL12B, PTGES, MERTK, ABCG1, CD5L	Inflammation of absolute anatomical region, Inflammation of body cavity, Inflammation of respiratory system component, Cell death of immune cells, Apoptosis of blood cells: Predicted activation
Day 3	1	11.333	MYD88, TICAM1, GFI1, IL33, IGE,NFKB, NFKB1, NOD2, FOS, IKBKB	IL1R1, EDNRB, HDC, IL10, ICAM1, MDM2, SMAD3, C5, GRN	Increased levels of creatinine: Predicted suppression
	2	10.436	JUNB, SMARCA4, STAT3, TNFSF11, IL1, IL1A, OSM, CHUK, IL6R, CD40LG, TGFB2, RELA	IFI16, CSF3, NOS3, IL11, IGF2, TNFRSF11B, RB1, SMAD3, NOTCH1, HES1	Increased activation of alkaline phosphatase: Predicted suppression
Day 7	1	3.175	TICAM1	IL12A, IRF7, CCL5, IFNG, TNF, IL1A, DDX58, CH25H, FPR1, ICAM1, CCRL2, IKBKE	Cell movement of blood cells: Predicted suppression
	2	3.175	TICAM1	IL12A, IRF7, CCL5, IFNG, TNF, IL1A, DDX58, CH25H, FPR1, ICAM1, CCRL2, IKBKE	Leukocyte migration: Predicted suppression
Day 14	1	4.025	IL1B	CCR7, ITGAM, OSM, ICOSLG/ LOC102723996, CCL10, IL1, TNF, IL1A, IL1B, IL17A, IL17F, IL17C, IL17D, IL17E, IL17F, IL17G, IL17H, IL17I, IL17J, IL17K, IL17L, IL17M, IL17N, IL17O, IL17P, IL17Q, IL17R, IL17S, IL17T, IL17U, IL17V, IL17W, IL17X, IL17Y, IL17Z, IL17AA, IL17AB, IL17AC, IL17AD, IL17AE, IL17AF, IL17AG, IL17AH, IL17AI, IL17AJ, IL17AK, IL17AL, IL17AM, IL17AN, IL17AO, IL17AP, IL17AQ, IL17AR, IL17AS, IL17AT, IL17AU, IL17AV, IL17AW, IL17AX, IL17AY, IL17AZ, IL17BA, IL17BB, IL17BC, IL17BD, IL17BE, IL17BF, IL17BG, IL17BH, IL17BI, IL17BJ, IL17BK, IL17BL, IL17BM, IL17BN, IL17BO, IL17BP, IL17BQ, IL17BR, IL17BS, IL17BT, IL17BU, IL17BV, IL17BW, IL17BX, IL17BY, IL17BZ, IL17CA, IL17CB, IL17CC, IL17CD, IL17CE, IL17CF, IL17CG, IL17CH, IL17CI, IL17CJ, IL17CK, IL17CL, IL17CM, IL17CN, IL17CO, IL17CP, IL17CQ, IL17CR, IL17CS, IL17CT, IL17CU, IL17CV, IL17CW, IL17CX, IL17CY, IL17CZ, IL17DA, IL17DB, IL17DC, IL17DD, IL17DE, IL17DF, IL17DG, IL17DH, IL17DI, IL17DJ, IL17DK, IL17DL, IL17DM, IL17DN, IL17DO, IL17DP, IL17DQ, IL17DR, IL17DS, IL17DT, IL17DU, IL17DV, IL17DW, IL17DX, IL17DY, IL17DZ, IL17EA, IL17EB, IL17EC, IL17ED, IL17EE, IL17EF, IL17EG, IL17EH, IL17EI, IL17EJ, IL17EK, IL17EL, IL17EM, IL17EN, IL17EO, IL17EP, IL17EQ, IL17ER, IL17ES, IL17ET, IL17EU, IL17EV, IL17EW, IL17EX, IL17EY, IL17EZ, IL17FA, IL17FB, IL17FC, IL17FD, IL17FE, IL17FF, IL17FG, IL17FH, IL17FI, IL17FJ, IL17FK, IL17FL, IL17FM, IL17FN, IL17FO, IL17FP, IL17FQ, IL17FR, IL17FS, IL17FT, IL17FU, IL17FV, IL17FW, IL17FX, IL17FY, IL17FZ, IL17GA, IL17GB, IL17GC, IL17GD, IL17GE, IL17GF, IL17GG, IL17GH, IL17GI, IL17GJ, IL17GK, IL17GL, IL17GM, IL17GN, IL17GO, IL17GP, IL17GQ, IL17GR, IL17GS, IL17GT, IL17GU, IL17GV, IL17GW, IL17GX, IL17GY, IL17GZ, IL17HA, IL17HB, IL17HC, IL17HD, IL17HE, IL17HF, IL17HG, IL17HH, IL17HI, IL17HJ, IL17HK, IL17HL, IL17HM, IL17HN, IL17HO, IL17HP, IL17HQ, IL17HR, IL17HS, IL17HT, IL17HU, IL17HV, IL17HW, IL17HX, IL17HY, IL17HZ, IL17IA, IL17IB, IL17IC, IL17ID, IL17IE, IL17IF, IL17IG, IL17IH, IL17II, IL17IJ, IL17IK, IL17IL, IL17IM, IL17IN, IL17IO, IL17IP, IL17IQ, IL17IR, IL17IS, IL17IT, IL17IU, IL17IV, IL17IW, IL17IX, IL17IY, IL17IZ, IL17JA, IL17JB, IL17JC, IL17JD, IL17JE, IL17JF, IL17JG, IL17JH, IL17JI, IL17JJ, IL17JK, IL17JL, IL17JM, IL17JN, IL17JO, IL17JP, IL17JQ, IL17JR, IL17JS, IL17JT, IL17JU, IL17JV, IL17JW, IL17JX, IL17JY, IL17JZ, IL17KA, IL17KB, IL17KC, IL17KD, IL17KE, IL17KF, IL17KG, IL17KH, IL17KI, IL17KJ, IL17KK, IL17KL, IL17KM, IL17KN, IL17KO, IL17KP, IL17KQ, IL17KR, IL17KS, IL17KT, IL17KU, IL17KV, IL17KW, IL17KX, IL17KY, IL17KZ, IL17LA, IL17LB, IL17LC, IL17LD, IL17LE, IL17LF, IL17LG, IL17LH, IL17LI, IL17LJ, IL17LK, IL17LL, IL17LM, IL17LN, IL17LO, IL17LP, IL17LQ, IL17LR, IL17LS, IL17LT, IL17LU, IL17LV, IL17LW, IL17LX, IL17LY, IL17LZ, IL17MA, IL17MB, IL17MC, IL17MD, IL17ME, IL17MF, IL17MG, IL17MH, IL17MI, IL17MJ, IL17MK, IL17ML, IL17MN, IL17MO, IL17MP, IL17MQ, IL17MR, IL17MS, IL17MT, IL17MU, IL17MV, IL17MW, IL17MX, IL17MY, IL17MZ, IL17NA, IL17NB, IL17NC, IL17ND, IL17NE, IL17NF, IL17NG, IL17NH, IL17NI, IL17NJ, IL17NK, IL17NL, IL17NM, IL17NO, IL17NP, IL17NQ, IL17NR, IL17NS, IL17NT, IL17NU, IL17NV, IL17NW, IL17NX, IL17NY, IL17NZ, IL17OA, IL17OB, IL17OC, IL17OD, IL17OE, IL17OF, IL17OG, IL17OH, IL17OI, IL17OJ, IL17OK, IL17OL, IL17OM, IL17ON, IL17OO, IL17OP, IL17OQ, IL17OR, IL17OS, IL17OT, IL17OU, IL17OV, IL17OW, IL17OX, IL17OY, IL17OZ, IL17PA, IL17PB, IL17PC, IL17PD, IL17PE, IL17PF, IL17PG, IL17PH, IL17PI, IL17PJ, IL17PK, IL17PL, IL17PM, IL17PN, IL17PO, IL17PP, IL17PQ, IL17PR, IL17PS, IL17PT, IL17PU, IL17PV, IL17PW, IL17PX, IL17PY, IL17PZ, IL17QA, IL17QB, IL17QC, IL17QD, IL17QE, IL17QF, IL17QG, IL17QH, IL17QI, IL17QJ, IL17QK, IL17QL, IL17QM, IL17QN, IL17QO, IL17QP, IL17QQ, IL17QR, IL17QS, IL17QT, IL17QU, IL17QV, IL17QW, IL17QX, IL17QY, IL17QZ, IL17RA, IL17RB, IL17RC, IL17RD, IL17RE, IL17RF, IL17RG, IL17RH, IL17RI, IL17RJ, IL17RK, IL17RL, IL17RM, IL17RN, IL17RO, IL17RP, IL17RQ, IL17RR, IL17RS, IL17RT, IL17RU, IL17RV, IL17RW, IL17RX, IL17RY, IL17RZ, IL17SA, IL17SB, IL17SC, IL17SD, IL17SE, IL17SF, IL17SG, IL17SH, IL17SI, IL17SJ, IL17SK, IL17SL, IL17SM, IL17SN, IL17SO, IL17SP, IL17SQ, IL17SR, IL17SS, IL17ST, IL17SU, IL17SV, IL17SW, IL17SX, IL17SY, IL17SZ, IL17TA, IL17TB, IL17TC, IL17TD, IL17TE, IL17TF, IL17TG, IL17TH, IL17TI, IL17TJ, IL17TK, IL17TL, IL17TM, IL17TN, IL17TO, IL17TP, IL17TQ, IL17TR, IL17TS, IL17TT, IL17TU, IL17TV, IL17TW, IL17TX, IL17TY, IL17TZ, IL17UA, IL17UB, IL17UC, IL17UD, IL17UE, IL17UF, IL17UG, IL17UH, IL17UI, IL17UJ, IL17UK, IL17UL, IL17UM, IL17UN, IL17UO, IL17UP, IL17UQ, IL17UR, IL17US, IL17UT, IL17UU, IL17UV, IL17UW, IL17UX, IL17UY, IL17UZ, IL17VA, IL17VB, IL17VC, IL17VD, IL17VE, IL17VF, IL17VG, IL17VH, IL17VI, IL17VJ, IL17VK, IL17VL, IL17VM, IL17VN, IL17VO, IL17VP, IL17VQ, IL17VR, IL17VS, IL17VT, IL17VU, IL17VV, IL17VW, IL17VX, IL17VY, IL17VZ, IL17WA, IL17WB, IL17WC, IL17WD, IL17WE, IL17WF, IL17WG, IL17WH, IL17WI, IL17WJ, IL17WK, IL17WL, IL17WM, IL17WN, IL17WO, IL17WP, IL17WQ, IL17WR, IL17WS, IL17WT, IL17WU, IL17WV, IL17WW, IL17WX, IL17WY, IL17WZ, IL17XA, IL17XB, IL17XC, IL17XD, IL17XE, IL17XF, IL17XG, IL17XH, IL17XI, IL17XJ, IL17XK, IL17XL, IL17XM, IL17XN, IL17XO, IL17XP, IL17XQ, IL17XR, IL17XS, IL17XT, IL17XU, IL17XV, IL17XW, IL17XX, IL17XY, IL17XZ, IL17YA, IL17YB, IL17YC, IL17YD, IL17YE, IL17YF, IL17YG, IL17YH, IL17YI, IL17YJ, IL17YK, IL17YL, IL17YM, IL17YN, IL17YO, IL17YP, IL17YQ, IL17YR, IL17YS, IL17YT, IL17YU, IL17YV, IL17YW, IL17YX, IL17YY, IL17YZ, IL17ZA, IL17ZB, IL17ZC, IL17ZD, IL17ZE, IL17ZF, IL17ZG, IL17ZH, IL17ZI, IL17ZJ, IL17ZK, IL17ZL, IL17ZM, IL17ZN, IL17ZO, IL17ZP, IL17ZQ, IL17ZR, IL17ZS, IL17ZT, IL17ZU, IL17ZV, IL17ZW, IL17ZX, IL17ZY, IL17ZZ	Adhesion of mononuclear leukocytes: Predicted suppression
	2	3.873	IL17A	TGFA, HBEGF, LIF, COL1A1, SLC2A1, IL6, FOS, TLR4, AREG, TNF, IL1A, TIMP1, CSF3, FAS, IL36G	Proliferation of connective tissue cells: Predicted suppression